Wire · operational-macro
FDA Approves Generic Lanreotide Injection for GEP-NETs
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 September 2026 · Fusion42 review
The FDA has approved a generic formulation of lanreotide injection for treating adult patients with unresectable, well- or moderately differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs), improving progression-free survival. The generic also has indications for acromegaly and carcinoid syndrome and carries a competitive generic therapy designation.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face lower entry barriers in GEP-NETs treatment as a new generic lanreotide injectables supplier with market access expanded by FDA's competitive generic therapy tag. Your manufacturing and supply reliability will determine success against incumbents with complex injectables.
◆ Coverage
1 source · 22 Sep 2026
◆ Related on Wire
◆ Topics